Recalls & Warnings
ConsumerLab.com is keeping you informed with current product recalls and warnings.
Posted March 8, 2012
Rx Drugs Found in Weight Loss and Enhancement Supplements
Laboratory analysis confirmed that SlimXtreme Herbal Slimming Capsule (SlimXtreme) contained the drug sibutramine, a controlled substance that was removed from the U.S. market in October 2010 for safety reasons. The drug ingredient is not listed on the product label. SlimXtreme poses a threat to consumers because the undeclared drug is known to substantially increase blood pressure and/or pulse rate in some patients and may present a significant risk for patients with a history of coronary artery disease, congestive heart failure, arrhythmias, or stroke. SlimXtrem may also interact in life threatening ways with other medications a consumer may be taking.
The affected lot number of SlimXtreme is SX 30 (exp 10.24.2012).
ViaXtreme Ultimate Sexual Enhancer Dietary Supplement for Men (ViaXtreme) was found to contain the drug sildenafil and related chemicals. Sildenafil is an active ingredient of an FDA approved drug for erectile dysfunction (ED). The drug ingredient is not listed on the product label. The undeclared ingredient may interact with nitrates found in some prescription drugs such as nitroglycerin and may lower blood pressure to dangerous levels. Consumers with diabetes, high blood pressure, high cholesterol, or heart disease often take nitrates. Additionally, ViaXtreme may cause side effects, such as headaches and flushing.
The affected lot numbers of ViaXtreme include A032111 3/13 and Lot 809013 09/12.
Consumers should stop using these products immediately and throw them away. Consumers who have experienced any negative side effects should consult a health care professional as soon as possible.
For information about supplements used for weight loss see ConsumerLab.com's Review of Weight Loss Supplements.
For information about sexual enhancement supplements see ConsumerLab.com's Review of Sexual Enhancement Supplements. The Warning Letter is available on the FDA website using the link below: